Pharmacists take on polypharmacy: can a bundled care model cut costs and improve safety?
NCT ID NCT07719907
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This study tests whether a clinical pharmacist-led bundled care model can reduce preventable polypharmacy—the use of unnecessary or potentially harmful multiple medications—in hospitalized adults. Participants are randomly assigned to receive either the pharmacist intervention plus usual care or usual care alone. The trial measures healthcare costs, medication appropriateness, hospital readmissions, and adverse drug events to see if this approach improves patient safety and reduces waste.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a clinical pharmacist-led bundled care model including medication reconciliation, review, deprescribing, and education
- What this could lead to
- If effective, this model could become a standard approach to reduce unnecessary medications, prevent drug-related harm, and lower healthcare costs in hospitals.
- What could go wrong
- This is a single-center study in Oman, so results may not apply elsewhere. The intervention depends on pharmacist availability and acceptance by medical teams, which may limit real-world impact.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 260 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2027
An estimate. Start dates often move.
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 18 years or older. * Admitted under an adult medical specialty at one of the participating hospitals. * Receiving five or more regular medications at the time of hospital admission. * Expected hospital stay of at least 48 hours. * Able and willing to provide written informed consent. Exclusion Criteria: * Admission under obstetric, pediatric, or psychiatric services. * Admission to an intensive care unit. * Terminal illness with an expected survival of less than three months. * Unable to provide informed consent and without an available legal representative. * Declines participation in the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Medication-related problems are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.